For instance, PET/CT together with magnetic resonance imaging demonstrated the synergistic effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and ARRY-142886 (AZD6244/selumetinib), an allosteric MEK inhibitor, on K-ras mutated tumor in a genetically engineered mouse model of lung adenocarcinoma [21]. Here, KRAS is linked to neoplasm.